Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8975 results

  1. Selinexor for maintenance treatment of p53 wild-type advanced or recurrent endometrial cancer after systemic treatment [TSID12374]

    Awaiting development Reference number: GID-TA12014 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]

    Awaiting development Reference number: GID-TA12004 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [TSID12394]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Crovalimab for treating atypical haemolytic uraemic syndrome [TSID12386]

    Awaiting development Reference number: GID-TA12006 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [TSID12375]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  7. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development Reference number: GID-TA11561 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [TSID12377]

    Awaiting development Reference number: GID-TA12000 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [TSID12376]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  11. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  12. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  13. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  14. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]

    Awaiting development Reference number: GID-TA11980 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development